Seaport Therapeutics Inc. opened trading with a 17% rally after an upsized initial public offering that lifted the company’s valuation. The biotech firm secured $255 million from investors, surpassing its original target and sparking immediate interest on the Nasdaq.

The aggressive pricing and strong secondary demand reflect optimism about Seaport’s pipeline, positioning it as a notable entry in the life‑science sector. Investors saw the deal as a bet on emerging therapies, pushing the stock higher on debut.

Market analysts view the uptick as a sign that fresh capital is still flowing into biotech, even as valuations tighten elsewhere. The $255 million raise provides Seaport with a solid runway to advance clinical studies and pursue strategic partnerships.

With its shares up 17% on the first day, Seaport’s debut underscores the sector’s resilience and the appetite for growth‑stage therapeutics.